Pfizer Q2 2026 Earnings
Rev. $15.03B (est $14.41B) - Raises Midpoint Of 2026 Rev. Guidance - Announces Expansion Of Productivity Initiatives - Eliquis Rev 2.43B (est 2.09B) - Prevnar Franchise Rev $1.34B (est $1.38B) - Now Expects Total Net Cost Savings Of $6.7 Billion - Still Sees FY Adj EPS $2.80 To $3.00 - Sees FY Rev. $60.5B To $62.5B, Saw $59.5B To $62.5B
Story updates
11:07:55 AM UTC
SquawkNews
Pfizer Q2 2026 Earnings
Rev. $15.03B (est $14.41B) - Raises Midpoint Of 2026 Rev.
Guidance - Announces Expansion Of Productivity Initiatives - Eliquis Rev 2.43B (est 2.09B) - Prevnar Franchise Rev $1.34B (est $1.38B) - Now Expects Total Net Cost Savings Of $6.7 Billion - Still Sees FY Adj EPS $2.80 To $3.00 - Sees FY Rev. $60.5B To $62.5B, Saw $59.5B To $62.5B